Alps Advisors Inc Aerie Pharmaceuticals Inc Transaction History

Alps Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 04, 2019	SELL	$33.0 - $60.04 $2.64 Million - $4.8 Million	-80,025 Closed	0 $0
Q3 2018 Oct 25, 2018	BUY	$56.15 - $73.9 $1.29 Million - $1.7 Million	23,058 Added 40.48%	80,025 $4.93 Million
Q2 2018 Aug 02, 2018	BUY	$47.85 - $70.45 $779,667 - $1.15 Million	16,294 Added 40.06%	56,967 $3.85 Million
Q2 2018 Jul 25, 2018	SELL	$47.85 - $70.45 $472,901 - $696,257	-9,883 Reduced 19.55%	40,673 $2.43 Million
Q1 2018 May 01, 2018	BUY	$51.15 - $61.0 $505,515 - $602,863	9,883 Added 24.3%	50,556 $2.74 Million
Q4 2017 Feb 05, 2018	BUY	$50.85 - $65.1 $248,300 - $317,883	4,883 Added 13.64%	40,673 $2.43 Million
Q3 2017 Nov 03, 2017	BUY	$48.6 - $60.1 $1.74 Million - $2.15 Million	35,790	35,790 $1.74 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.